Evidence map›Paper›PMID 37856011›Full record

ArticleMolecular biotechnology2024

EXOSC2 Mediates the Pro-tumor Role of WTAP in Breast Cancer Cells via Activating the Wnt/β-Catenin Signal.

Chen-Guang Lv, Yao Cheng, Lei Zhang, Guo-Gang Wu, Chun-Yan Liang, Zuo Tao, Bo Chen

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Methylation marks breast cancer metastasis: The roles of mThe Journal of biological chemistry · 2026
    Review
  2. Review
  3. Article
  4. Targeting RNA adenosine editing and modification enzymes for RNA therapeutics.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Chen-Guang Lv *Department of General Surgery, General Hospital of Northern Theater Command, Shenyang, People's Republic of China.
Yao Cheng *Department of Oncology, Panjin Central Hospital, Panjin, People's Republic of China.
Lei ZhangDepartment of Breast Surgery, The First Hospital of China Medical University, No. 155, Nanjing North Street, Shenyang, People's Republic of China.
Guo-Gang WuDepartment of Thyroid and Breast Surgery, Ansteel Group General Hospital, Anshan, People's Republic of China.
Chun-Yan LiangDepartment of Oncology, The Fourth Affiliated Hospital of China Medical University, Shenyang, People's Republic of China.
Zuo TaoDepartment of General Surgery, General Hospital of Northern Theater Command, Shenyang, People's Republic of China.
Bo ChenDepartment of Breast Surgery, The First Hospital of China Medical University, No. 155, Nanjing North Street, Shenyang, People's Republic of China. chenbocmu@sina.com.ORCID http://orcid.org/0009-0003-2725-2558
First Hospital of China Medical University · CNGeneral Hospital of Shenyang Military Region · CNAnsteel (China) · CNFourth Affiliated Hospital of China Medical University · CNJiangjin Central Hospital · CN

Funding

"Double First-Class": Clinical Medicine Symbolic Achievement Support Program of the Office of Development and Planning, China Medical University 3110200339Program of the Distinguished Professor of Liaoning Province, Breast Cancer 28019Subject Development Project of China Medical University 3110117053Tackling Key Problems and Serving Local Projects of Liaoning Province ZF20190006
6 · The paper itself

Abstract

BC (breast cancer) is the leading cause of cancer death in women. Exosome component 2 (EXOSC2), an RNA exosome component, is elevated in BC tissues and may relate to BC carcinogenesis. In this work, the high EXOSC2 expression was correlated with TNM (Tumor Node Metastasis) stage. Moreover, overexpression of EXOSC2 enhanced tumorigenic capacity of BC cells via facilitating cell proliferation and cell cycle progression, increasing migration and angiogenesis, as well as exacerbating xenograft formation in vivo. Whereas, EXOSC2 knockdown showed anti-cancer effects, including inhibition of cell proliferation and angiogenesis. Mechanistically, EXOSC2 activated the wnt/β-catenin pathway, which was also abolished by EXOSC2 knockdown. In addition, there were m6A methylation modification sites in the mRNA of EXOSC2. WTAP (Wilms tumor 1-associated protein) bound to EXOSC2 mRNA and increased its m6A methylation, resulting in extending the half-life of EXOSC2 mRNA. Luciferase data also confirmed that WTAP enhanced EXOSC2 mRNA stability through binding with the 3'-UTR containing m6A sites. Furthermore, WTAP silencing exhibited cancer-inhibiting effects on cell viability, cell cycle progression and tube formation, which was effectively reversed by EXOSC2 overexpression. In conclusion, our results demonstrate that EXOSC2 promotes the malignant behaviors of BC cells via activating the wnt/β-catenin pathway. In addition, EXOSC2 mediates the function of WTAP which contributes to the m6A modification of EXOSC2. Totally, this study suggested that EXOSC2 mediated the pro-tumor role of WTAP via activating the wnt/β-catenin signal.

Indexed as

Breast NeoplasmsCell ProliferationGene Expression Regulation, NeoplasticRNA-Binding ProteinsWnt Signaling PathwayAnimalsbeta CateninCell Line, TumorCell MovementFemaleHumansMiceMice, NudeMiddle AgedRNA Stabilitybeta CateninRNA-Binding ProteinsBCEXOSC2m6AWnt/β-cateninWTAP

Identifiers

PMID37856011
OpenAlexW4387765618

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.